Browse by author
Lookup NU author(s): Tomasz Zaremba, Huw ThomasORCiD, Mike Cole, Professor Ruth Plummer, Professor Nicola CurtinORCiD
Monozygotic twins provide an excellent tool to study environmental effects on human health. Poly(ADP-ribose) polymerase-1 (PARP-1) is an important enzyme primarily involved in DNA repair and genomic stability and is under clinical investigation as a target for anticancer therapy. As a part of a PARP pharmacogenetics study, elderly male monozygotic twins, one healthy and the other with a Trojani grade 3 sarcoma treated with doxorubicin (DOX: 142.5 mg/m(2)), were recruited for the study. PARP activity and expression were measured in peripheral blood mononuclear cells (PBMCs) by methods validated to GCLP standard and used as a pharmacodynamic endpoint for clinical trials. The mean PARP activity for the patient before treatment was 160 pmol PAR/10(6) cells and was similar to that of his brother (130 pmol PAR/10(6) cells). There was approximately ninefold decrease (P = 0.001) in PARP activity in a second sample from the patient taken 21 days after the first DOX administration (17 pmol PAR/10(6) cells) and a decrease in PARP-1 expression. Investigations into BALB/C mice revealed that DOX treatment (5 mg/kg) resulted in a significant transient decrease in PARP activity after 1 h (63% control, P a parts per thousand(a) 0.05) and 24 h (53% control, P a parts per thousand(a) 0.05) but that PARP activity was restored 1 week after DOX treatment (86% control, P = 0.24). We showed here that administration of DOX can have a profound effect on the measured level of PARP activity and expression in PBMCs from patients and animals. Results obtained in clinical trials where PARP activity is used as a pharmacodynamic marker of PARP inhibition could reflect the effect of a chemotherapeutic on PBMCs rather than the effectiveness of a tested PARP inhibitor.
Author(s): Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ
Publication type: Article
Publication status: Published
Journal: Cancer Chemotherapy and Pharmacology
Year: 2010
Volume: 66
Issue: 4
Pages: 807-812
Print publication date: 01/09/2010
Date deposited: 28/10/2010
ISSN (print): 0344-5704
ISSN (electronic): 1432-0843
Publisher: Springer
URL: http://dx.doi.org/10.1007/s00280-010-1359-0
DOI: 10.1007/s00280-010-1359-0
Altmetrics provided by Altmetric
